Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million

March 17, 2022

AUSTIN, Texas, and HAMILTON, Ontario, March 17, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. The Series A extension featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.

“Our proprietary TAC technology platform offers an innovative approach to developing novel autologous and allogeneic treatments for solid tumors, and we are excited to advance our pipeline through 2022 and beyond.”